Day: November 14, 2020

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that Bobak Azamian, M.D., Ph.D., CEO of Tarsus, will present an overview of the company at the Jefferies Virtual London Healthcare Conference, being held November 17-19.Presentation DetailsDate: Thursday, November 19Time: 11:10 AM GMT/ 6:10 AM EST/ 3:10 AM PSTWebcast: https://wsw.com/webcast/jeff141/tars/1861050The live webcast will be hosted on ir.tarsusrx.com and available for replay for a period of 90 days.In addition to the presentation, the management team will host investor meetings at the conference....

Continue reading

Aura Minerals Releases Its Third Quarter 2020 Financial and Operational Results

Written by Customer Service on . Posted in Public Companies.

ROAD TOWN, British Virgin Islands, Nov. 13, 2020 (GLOBE NEWSWIRE) — Aura Minerals, Inc. (“Aura Minerals” or the “Company”) announces that the Company has filed today its interim financial statements for the third quarter of 2020, its associated management’s discussion and analysis and related certification filings for the third quarter of 2020 (collectively, the “Third Quarter Results”).Rodrigo Barbosa, CEO of Aura, comments: “We at Aura are very pleased with both our quarterly results and the new trajectory for the company. Not only did we start this quarter with a successful IPO in Brazil, significantly strengthening our balance sheet and our support base, but also we delivered on our promises: Stronger production, lower cost and continued profit growth. Today, we published another record high result for Aura. Our team was able...

Continue reading

FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease

Written by Customer Service on . Posted in Public Companies.

FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease                                                                                                                                                           *     Complete Response Letter refers to deficiencies from a pre-license inspection of a third-party manufacturing facilityPARIS – November 14, 2020 – The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease.The CRL refers to certain deficiencies identified by the agency during a pre-license inspection of a third-party facility responsible for manufacturing....

Continue reading

La FDA publie une lettre de réponse complète au sujet du sutimlimab, un médicament expérimental pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides

Written by Customer Service on . Posted in Public Companies.

La FDA publie une lettre de réponse complète au sujet du sutimlimab, un médicament expérimental pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides*     La lettre de réponse complète se rapporte aux carences issues d’une inspection préalable à l’approbation de la demande de licence menée auprès d’une installation tierce responsable de la fabrication.PARIS – Le 14 novembre 2020 – La Food and Drug Administration des États-Unis a publié une lettre de réponse complète (CRL, Complete Response Letter) au sujet de la demande de licence de produit biologique (BLA, Biologics License Application) relative au sutimlimab, un anticorps monoclonal expérimental pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides (MAF).  Cette lettre se rapporte à certaines...

Continue reading

FMO Announces Accrual for Income Tax Expense

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Fiduciary/Claymore Energy Infrastructure Fund (“FMO” or the “Fund”) today announced a change in the estimate of the accrual of federal and state income tax expense caused by sales of investments. The Fund’s net asset value per share (“NAV”), which was impacted on November 13, 2020, is $6.20, which takes into account such accrual. The accrual is estimated, and the Fund’s actual tax liability could vary.The Fund is generally subject to U.S. federal income tax on its taxable income at the 21% rate applicable to corporations and, in addition, is subject to various state income taxes. The Fund accrues estimated current federal and state income tax expense based on current income and gains generated from its underlying investments and trading activity. Any net current or deferred income tax expense...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.